期刊文献+

基因型1型慢性丙型肝炎的新的标准治疗方案 被引量:3

A new standard treatment protocol for genotype 1 chronic hepatitis C
下载PDF
导出
摘要 目的:慢性丙型肝炎是严重的公共卫生问题。近年来,抗丙型肝炎病毒药物有了新的发展,相关治疗指南也有相应更新,故有必要介绍这些重要的进展。方法:进行文献检索,对抗病毒药物的研究进展进行综述。结果:已有两个直接作用的抗病毒药物即博赛泼维和特拉泼维进入临床应用,并被推荐联合聚乙二醇α-干扰素和利巴韦林作为治疗基因型1型慢性丙型肝炎的新的标准治疗方案。结论:研究提示,现有的聚乙二醇α-干扰素联合利巴韦林的标准治疗方案再联合博赛泼维或特拉泼维已成为基因型1型慢性丙型肝炎的新的标准治疗方案。 Objective: Hepatitis C is a serious public health problem. There is some new progress of antiviral agents in recent years and practice guidelines are also updated, thus it's necessary to introduce these important progresses. Methods: The research progress of anti-virus drug was summarized by searching literatures. Results: Two antiviral agents of boceprevir and telaprevir which have direct actions have been approved in clinical application. They are recommended in combination of peginterferon alfa and ribavirin as a new standard optimal therapy for genotype 1 chronic hepatitis C. Conclusion: The research suggests that the present standard treatment protocol of peginterferon alfa combined with ribavirin and then jointed boceprevir or telaprevir has become the new standard treatment protocol for genotype 1 chronic hepatitis C.
出处 《上海医药》 CAS 2013年第11期11-13,17,共4页 Shanghai Medical & Pharmaceutical Journal
关键词 丙型肝炎 标准治疗方案 博赛泼维 特拉泼维 hepatitis C standard treatment protocol boceprevir telaprevir
  • 相关文献

参考文献2

二级参考文献4

共引文献311

同被引文献26

  • 1丙型肝炎防治指南[J].临床肝胆病杂志,2004,20(4):197-203. 被引量:735
  • 2HOFMANN WP, ZEUZEM S. A new standard of care for the treatment of chronic HCV infection [ J ]. Nat Rev Gastroen- terof Hepatot, 2011, 8(5) : 257 -264.
  • 3GRANDINI E, CANNOLETTA F, SCUTERI A, et al. Immuno- logical modifications during treatment with thymosin alpha I plus antiviral, therapy in chronic hepatitis C [ J ]. Ann NY Acad Sci, 2010, 1194: 147 -152.
  • 4LEE MH, YANG HI, JEN CL, et al. Community and personal riskfactors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991 -2[J]. Gut, 2011,60(5) : 688 -694.
  • 5LI J, LIU CH, WANG FS. Thymosin alpha 1 : biological activi- ties, applications and genetic engineering production [ J ]. Peptides, 2010, 31 (11); 2151 -2158.
  • 6MORENO C, DELTENRE P ened treatment duration in PAWLOTSKY JM, et al. Short- treatment -naive genotype 1 HCV patients with rapid virological response., a meta -analy- sis[J]. J Hepatol, 2010, 52(1 } : 25 -31.
  • 7LOK AS, EVERHART JE, WRIGHT EC, et al. Maintenance peginterferon(peglFN) therapy to prevent hepatocellular car- cinoma(HCC) in patients with advanced chronic hepatitis C: extended follow- up results from the HALT -C Trial [ J ]. Hepatology, 2010, 52 (Suppl) : 428a -429a.
  • 8周朝晖,余为民.α_1-干扰素、利巴韦林联合α_1胸腺素治疗慢性丙型肝炎疗效观察[J].肝脏,2008,13(1):96-97. 被引量:6
  • 9段虎平,孟红霞.胸腺肽α_1预防化疗所致白细胞减少的疗效观察[J].中国现代医生,2008,46(5):115-115. 被引量:1
  • 10魏来.慢性丙型肝炎治疗:更多的机遇,更多的挑战[J].中华肝脏病杂志,2009,17(7):481-483. 被引量:5

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部